Compare BHM & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHM | IXHL |
|---|---|---|
| Founded | 2022 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 37.0M |
| IPO Year | 2022 | 2024 |
| Metric | BHM | IXHL |
|---|---|---|
| Price | $9.28 | $3.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 4.8K | ★ 241.9K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $68,734,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.88 | N/A |
| 52 Week Low | $8.05 | $0.16 |
| 52 Week High | $14.50 | $6.39 |
| Indicator | BHM | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 41.34 |
| Support Level | $8.05 | $3.07 |
| Resistance Level | $9.60 | $4.12 |
| Average True Range (ATR) | 0.19 | 0.25 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 9.73 |
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The company has two reportable segments, consisting of Residential Communities, which derives maximum revenue; and Scattered Single-family homes.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.